Close Menu

TGen

Launched by both national labs and regional and specialty firms, the offerings provide testing as well as guidance on how to best structure testing programs.

The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.

The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.

Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.